Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05916248 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL: Personalized neoantigen tumor vaccine
BIOLOGICAL: PD-1 inhibitor

Sponsor

Ruijin Hospital

Collaborators

[object Object]